Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000180025 | SCV000232369 | benign | not specified | 2014-11-12 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000197803 | SCV000252901 | benign | Brugada syndrome 4 | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000248968 | SCV000319062 | likely benign | Cardiovascular phenotype | 2015-09-15 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000180025 | SCV001361009 | benign | not specified | 2019-05-27 | criteria provided, single submitter | clinical testing | Variant summary: CACNB2 c.711G>A alters a conserved nucleotide resulting in a synonymous change. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0034 in 250822 control chromosomes in the gnomAD database, including 2 homozygotes. The observed variant frequency is approximately 339 fold of the estimated maximal expected allele frequency for a pathogenic variant in CACNB2 causing Arrhythmia phenotype (1e-05), strongly suggesting that the variant is benign. c.711G>A has been reported in the literature in patients with Autistic Spectrum Disorder (Breitenkamp_2014). This report however, does not provide unequivocal conclusions about association of the variant with Arrhythmia. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (2x benign/likely benign and 1x uncertain significance). Based on the evidence outlined above, the variant was classified as benign. |
Gene |
RCV001711469 | SCV001945250 | benign | not provided | 2015-03-03 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000197803 | SCV002048161 | likely benign | Brugada syndrome 4 | 2021-03-13 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001711469 | SCV004126521 | likely benign | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | CACNB2: BP4, BS2 |
Clinical Genetics, |
RCV000180025 | SCV001921623 | benign | not specified | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000180025 | SCV001951114 | benign | not specified | no assertion criteria provided | clinical testing |